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Abstract
Development of specific inhibitors of allergy has had limited success, in part, owing to a lack of
experimental models that reflect the complexity of allergen-IgE interactions. We designed a
heterotetravalent allergen (HtTA) system, which reflects epitope heterogeneity, polyclonal
response and number of immunodominant epitopes observed in natural allergens, thereby
providing a physiologically relevant experimental model to study mast cell degranulation. The
HtTA design revealed the importance of weak-affinity epitopes in allergy, particularly when
presented with high-affinity epitopes. The effect of selective inhibition of weak-affinity epitope-
IgE interactions was investigated with heterobivalent inhibitors (HBIs) designed to simultaneously
target the antigen- and nucleotide-binding sites on the IgE Fab. HBI demonstrated enhanced
avidity for the target IgE and was a potent inhibitor of degranulation in vitro and in vivo. These
results demonstrate that partial inhibition of allergen-IgE interactions was sufficient to prevent
mast cell degranulation, thus establishing the therapeutic potential of the HBI design.
Type I hypersensitivity (allergy) is a disorder of the immune system that occurs when the
adaptive immune system is directed against substances in the environment that would
otherwise be harmless. Immediate hypersensitivity initiates when IgE antibodies bound to
their high-affinity receptor (FcεRI) on mast cells are cross-linked by multivalent allergens,
leading to mast cell degranulation1,2. Naturally occurring allergens are typically complex,
structurally heterogeneous proteins, with multiple allergy-inducing epitopes. Accordingly,
the IgE antibodies that are generated against these proteins are polyclonal in nature and bind
their respective epitopes with a range of affinities3,4. Typical allergens have two to twelve
epitopes that are recognized by polyclonal IgE antibodies5–8. Recent evidence suggests that
Correspondence and requests for materials should be addressed to B.B.
*bbilgicer@nd.edu
Author contributions: B.B. supervised and coordinated all of the research activities, designed the experiments and funded the study.
M.W.H designed the experiments, synthesized and characterized all of the molecules, performed the in vitro experiments and analyzed
all of the data. T.K. designed and supervised the in vitro assays. M.H.K. designed and supervised the in vivo studies. A.P.S. performed
the in vivo experiments. M.W.H., T.K. and B.B. wrote the manuscript.
Competing financial interests: The authors declare no competing financial interests.
Additional information: Supplementary information and chemical compound information is available in the online version of the
paper. Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.
NIH Public Access
Author Manuscript
Nat Chem Biol. Author manuscript; available in PMC 2014 December 01.
Published in final edited form as:
Nat Chem Biol. 2013 December ; 9(12): 789–795. doi:10.1038/nchembio.1358.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
among the identified epitopes on a given allergen, only one to five are immunodominant,
meaning they are involved in the degranulation response observed in the majority of patients
with that particular allergy7,9– 11. For example, the peanut allergen Ara h 3, the wheat
allergen Tri a 14 and the melon allergen Cuc m 2 were each found to have four distinct
epitopes triggering the allergic reaction6,12,13. Additionally, the melon allergen was found to
have two high-binding and two low-binding IgE epitopes (Fig. 1a)4,14.
Owing to the complexity of natural allergens, it has been a challenge to develop
experimental models that mimic natural allergic responses. As a result, most allergy studies
are performed using dinitrophenyl (DNP) with DNP-specific IgE (IgEDNP) as the hapten-
antibody pair15–19. The DNP-IgEDNP system uses monoclonal IgEDNP to bind the IgE
receptor, FcεRI, on mast cells. After the mast cells are primed with IgEDNP, cross-linking is
induced with DNP-conjugated synthetic allergens typically synthesized using BSA, human
serum albumin or ovalbumin as the scaffold. Despite the prevalence of this model, it has
several shortcomings. First, DNP binds IgEDNP with an atypically high affinity, which is not
representative of the broad range of affinities IgEs have for natural allergy epitopes10,13,20.
Second, the hapten conjugation methods used are nonspecific, resulting in heterogeneous
synthetic allergens containing 2 to 25 haptens, which is far more than the number of allergy-
inducing epitopes found in natural allergens16–18. Furthermore, the heterogeneity of these
synthetic allergens complicates interpretation of results as the precise number and
orientation of the haptens are unknown, and some haptens may be unavailable to bind
surface-bound IgE owing to steric constraints21,22. Finally, multiple presentations of the
same hapten on a synthetic allergen do not accurately represent the multiple distinct epitopes
on a natural allergen3,4. Although previous studies using the DNP-IgEDNP model have
provided important insight into mast cell degranulation, they fall short in modeling the
complexity of natural allergen-IgE interactions.
In this study, we developed a well-defined, multicomponent experimental system that
enabled an integrative approach to study mast cell degranulation (Fig. 1b,c). Specifically, in
our design, we incorporated (i) epitope heterogeneity, (ii) IgE antibody variability, (iii)
range of epitope-IgE affinities and (iv) relevant epitope valency observed in natural
allergens to better reflect the complexity of allergen-IgE interactions. This was
accomplished through the design of a tetravalent scaffold that allowed four haptens to bind
simultaneously to four different IgE antibodies. The flexibility of the design allowed for the
simultaneous presentation of four identical haptens, homotetravalent allergens (HmTAs), or
two sets of two haptens, HtTAs. In our design, we also controlled the affinities of the IgE-
hapten interactions by using multiple IgE-hapten pairs and by chemically modifying the
haptens to reflect the range of the epitope-IgE affinities present in physiological systems.
The tetravalent allergen design provided a more realistic representation of natural allergens
and allowed us to investigate the role of weak-affinity epitopes when presented alone or
with high-affinity epitopes on a single allergen. Our results demonstrated that low-affinity
epitopes have a major role in eliciting an allergic response when presented in combination
with high-affinity epitopes.
Next, we evaluated the therapeutic potential of selective inhibition of weak-affinity epitope-
IgE interactions by taking an engineering approach where we designed selective and
targeted inhibitors (HBIs) of weak-affinity interactions by using the conserved nucleotide-
binding site found on the Fab domain of IgE antibodies (Fig. 1d). Through a combination of
molecular modeling and experimental approaches, we have extensively characterized this
underused site and demonstrated that this binding site is conserved across all
immunoglobulins17,23. In addition, our analysis demonstrated that the conformation of the
four residues that make up this binding site, two tyrosine residues on the light chain and one
tyrosine and one tryptophan on the heavy chain, are also highly conserved17,24,25.
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Previously, we described in detail the design, synthesis and characterization of HBIs that
selectively inhibited allergen binding to IgE antibody, thereby inhibiting mast cell
degranulation in a variant of the commonly used DNP-IgEDNP model17. HBIs were
composed of a hapten molecule conjugated to a nucleotide-binding site ligand, which
enabled simultaneous targeting of the antigen-binding site as well the nucleotide-binding site
located on the Fab domain of all antibodies (Fig. 1d). Simultaneous bivalent binding to both
of these sites provided the HBIs with enhanced avidity and selectivity for the target IgE and
enabled competitive inhibition of allergen binding. In this study, we demonstrated that an
HBI designed to selectively inhibit only the weak-affinity epitope-IgE interactions of a
HtTA consisting of high- and low-affinity haptens was sufficient to prevent degranulation in
both in vitro and in vivo allergy models (Fig. 1e). Taken together, the HtTA design provided
an experimental tool to elucidate formerly unrevealed aspects of mast cell degranulation,
and the HBI design provided us with a new antibody-targeting approach with therapeutic
potential to selectively inhibit allergic responses.
Results
Design and characterization of tetravalent allergens
Previous methods of synthesizing allergens use nonspecific chemical methods to conjugate
haptens to protein scaffolds, resulting in poorly defined allergens that complicate
interpretation of results15–18,21,22. To address this problem, we synthesized well-defined and
well-characterized tetravalent allergens with the criteria that each of the four haptens bound
a different IgE. Through a combination of experimental approaches and molecular
modeling, it has been demonstrated that the average distance between the two Fab domains
of IgE is 11–13 nm and that, owing to the differences between the extended and in-solution
length of ethylene glycol, a PEG3350 linker (extended length of 29 nm) is required to span
the two antigen-binding sites on a single IgE26–28. Previously, we identified that ethylene
glycol with an extended length of ∼6 nm is optimal for haptens to bind multiple antibodies
without bridging the two antigen-binding sites on a single antibody29–33. Consequently, in
our tetravalent allergen design, the four hapten moieties were conjugated to the core of the
molecule with 8 units of ethylene glycol, which provided an extended length of 3.2 nm,
yielding a maximum separation of 6.4 nm between haptens (Fig. 2a,b). The resulting
separation distance between haptens was substantially shorter than the length required for
bivalent binding to a single IgE, ensuring that the tetravalent allergen cross-linked the
neighboring IgE molecules on mast cells rather than the two Fab arms of a single IgE28.
Lysine residues were incorporated into the scaffold to provide a means of conjugating each
moiety to the ethylene glycol linker as well as to provide a charge to increase the solubility
of the synthetic allergens. The flexibility and solubility of the tetravalent scaffold ensured
that each hapten was available to bind an IgE antibody, yet the length of the ethylene glycol
linker made it sterically unfavorable for a single IgE to bind bivalently to a single tetravalent
allergen.
The next step was the identification of haptens with a broad range of affinities for IgE
antibodies to reflect the range of affinities found in natural allergy systems. To identify the
high-affinity and low-affinity haptens, we determined the monovalent binding affinities of
several hapten-IgE pairs using a previously described fluorescence quenching method17. Out
of the screened candidates, dansyl-IgEdansyl was identified as a high-affinity pair with a
monovalent Kddansyl = 54 ± 4 nM (Fig. 3a). To identify a hapten-IgE pair that could be used
to represent the weak-affinity interactions, we modified the commonly used DNP-IgEDNP
pair. Although DNP binds IgEDNP with high affinity, we established that nitrofuran (NF)
binds IgEDNP with a monovalent KdNF of 41 ± 4 μM (Fig. 3a). The dansyl-IgEdansyl and NF-
IgEDNP pairs provided a 760-fold difference in affinity, allowing us to model both the high-
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and low-affinity epitopes found in natural allergy systems. Notably, inclusion of two
different IgE-hapten pairs in our design provided a closer approximation to physiological
conditions, where multiple clones of IgEs are involved in mast cell degranulation (Fig. 1b,c).
The HtTA design provided that a degranulation response will only occur if both hapten-
specific IgEs are present on the mast cell surface; if only one of the respective IgEs is
present, the HtTA will essentially behave as a bivalent ligand, which is insufficient for
triggering degranulation34,35. As a first step in demonstrating that both hapten-IgE pairs are
necessary for degranulation, we assessed any cross-reactivity between the two haptens; NF
did not cross-react with IgEdansyl, and, similarly, dansyl did not cross-react with IgEDNP
(Supplementary Results, Supplementary Fig. 1).
Next, we synthesized a series of tetravalent synthetic allergens using Fmoc chemistry on a
solid support (Fig. 2b). Conjugation of dansyl to the tetravalent scaffold, with a valency of 4,
provided us with a high-affinity HmTA (HmTA [dansyl4]; 1), whereas conjugation of NF to
the tetravalent scaffold, with a valency of 4, provided us with a low-affinity HmTA (HmTA
[NF4]; 2). Notably, conjugation of both dansyl and NF to the tetravalent scaffold, each with
a valency of 2, provided us with HtTA [dansyl2NF2] (3) to elucidate the role weak-affinity
epitopes have in mast cell degranulation when presented in combination with high-affinity
epitopes on the same allergen. Homobivalent allergen dansyl (HmBA [dansyl2]; 4), which
has the same structure as HtTA [dansyl2NF2] except for two acetylated arms instead of NF,
was also synthesized for use as a control.
After synthesizing the tetravalent allergens, it was necessary to characterize the molecules to
ensure that each hapten was available for simultaneous binding to a separate IgE antibody.
This was accomplished by analyzing the complexes formed by a stoichiometric mixture of
IgE antibodies to tetravalent allergens (2:1) using dynamic light scattering. The results of a
representative experiment performed by mixing HtTA [dansyl2NF2] with 2 molar
equivalents of IgE (50:50 mixture of IgEDNP and IgEdansyl) are shown in Figure 3b.
Although IgE antibodies had an average hydrodynamic diameter of 10 nm (Fig. 3b),
addition of HtTA [dansyl2NF2] to the antibody mixture rapidly resulted in the formation of
complexes with a hydrodynamic diameter of 20 nm (Fig. 3b). Markedly, the signal at 10 nm
completely disappeared, indicating that all of the monomeric IgEs were sequestered by the
tetravalent allergen. Thermodynamic equilibrium was reached in less than 1 min, and
complexes were stable over several hours. Similarly, HmTA [dansyl4] formed complexes
with a hydrodynamic diameter of 20 nm with IgEdansyl and, as expected, did not form
complexes with IgEDNP (Supplementary Fig. 2). The allergen HmTA [NF4] did not form
complexes with IgEDNP owing to the low affinity of the NF-IgEDNP interaction
(Supplementary Fig. 2). On the basis of these results and the design of the tetravalent
scaffold, we concluded that the structure formed was a bicyclic tetramer consisting of four
IgEs and two tetravalent allergens (IgE4HtTA2 or IgE4HmTA2). The only other possible
structure with a hydrodynamic diameter of 20 nm with complete sequestration of IgE is two
IgEs binding a single tetravalent allergen (IgE2HtTA or IgE2HmTA); however, this was
eliminated as a possibility on the basis of the design of the tetravalent allergens. Efficient
cross-linking of two Fabs on a single IgE requires a hapten separation distance of 11–13 nm,
which is substantially longer than the maximum separation distance between haptens in our
design28,33,36. Additionally, the binding of HtTA [dansyl2NF2] to IgEdansyl, IgEDNP and an
equimolar solution of both IgEs was evaluated using the previously described fluorescence
quenching technique17. There was a 3.3-fold increase in the affinity of HtTA [dansyl2NF2]
for IgEDNP in the presence of IgEdansyl compared to IgEDNP alone, thus providing further
evidence for the formation of a bicyclic tetramer consisting of four IgEs and two tetravalent
allergens (Supplementary Fig. 3). The complexes were not stable for the ∼10 min required
for size-exclusion chromatography analysis owing to the weak-affinity haptens. Combined,
these results indicated that each hapten on the tetravalent allergen was simultaneously bound
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to a different IgE, demonstrating that binding of four IgE molecules to the tetravalent
allergen was not sterically hindered.
Tetravalent allergens induce degranulation in vitro
Hapten-conjugated BSA is a poor model of natural allergens. However, BSA conjugates
have been shown to be potent stimulators of allergic responses15–17. Therefore, we first used
hapten-conjugated BSA to optimize our system and assess any cross-reactivity between the
antibody-hapten pairs by using the well-established rat basophilic leukemia (RBL) mast cell
degranulation model. RBL cells were primed with IgEDNP, IgEdansyl or an equimolar
solution of both antibodies. The relative amounts of each IgE on the surface of the mast cells
reflected the relative IgE ratios in solution, as determined using a fluorescein-DNP ligand
(Supplementary Fig. 4). Our results with BSA allergens dansyl14-BSA and NF17-BSA (14
and 17 average haptens per BSA respectively) demonstrated that both allergens triggered
degranulation when the RBL cells were primed with the hapten-specific IgE or the
equimolar solution of both antibodies (Fig. 4a). The lack of a response by cells primed with
IgEDNP using dansyl14-BSA as the allergen or cells primed with IgEdansyl using NF17-BSA
as the allergen demonstrated the specificity of each hapten for the corresponding IgE. These
results were consistent with the monovalent affinity assays and further demonstrated that
there was no cross-reactivity between the hapten-IgE pairs. This result indicates that (i) both
antibodies were able to bind the FcεRI receptors on the cell surface, (ii) the presence of
either antibody did not inhibit the other from binding to its hapten and (iii) maximum
degranulation does not require complete cross-linking of mast cell–bound IgE. These control
experiments validated that RBL cells primed with both IgEDNP and IgEdansyl antibodies
provide a suitable experimental system to test the tetravalent synthetic allergens.
Next, we evaluated HmTA [dansyl4], HmTA [NF4] and HtTA [dansyl2NF2]. HmTA
[dansyl4] proved to be the most potent allergen, stimulating a bell-shaped dose response
from 5 nM to 5 μM with a maximum response at 500 nM (Fig. 4b). Conversely, HmTA
[NF4] did not initiate a degranulation response. Markedly, HtTA [dansyl2NF2], which is
composed of both dansyl and NF haptens, each with a valency of 2, stimulated a bell-shaped
degranulation response from 50 nM to 5 μM, similar to HmTA [dansyl4], with a maximum
response occurring at 500 nM. These results were in agreement with our previous work
performed with homotetravalent allergens, where we determined that a hapten must have a
Kd <235 nM to stimulate a response29. These results suggested a mechanism of activation
where a single hapten binds a single IgE on the surface of a mast cell, and then the allergen–
IgE complex diffuses laterally across the surface of the mast cell until a second IgE is
encountered, and the hapten binds the second IgE, thus cross-linking the receptors.
Accordingly, a HmTA with low-affinity haptens will not stay bound to an IgE long enough
for complexes to form29,33. Control experiments were performed with HmBA [dansyl2],
which did not stimulate a response under any condition. These results were consistent with
previous literature reports that bivalent allergens are incapable of stimulating
degranulation34,35. Combined, these results indicate that the response observed with HtTA
[dansyl2NF2] was not due to the dansyl moieties alone (Fig. 4b). Additional control
experiments were performed with increased allergen exposure time and increased allergen
concentrations. HmTA [dansyl4] and HtTA [dansyl2NF2] reached their maximum
degranulation potential at ∼60 min, whereas HmTA [NF4] and HmBA [dansyl2] did not
induce degranulation even when the allergen exposure time was increased to 120 min (Fig.
4c). These observations did not change even when the HmTA [NF4] and HmBA [dansyl2]
concentration was increased to 10 μM (Supplementary Fig. 5). Given that the individual
components of HtTA (HmTA [NF4] and HmBA [dansyl2]) failed to elicit a degranulation
response, these results illustrate the importance of low-affinity epitopes in mast cell
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degranulation, particularly when presented simultaneously with high-affinity epitopes on the
same allergen.
HBI inhibits mast cell degranulation in vitro
Previously, we described HBIs that selectively inhibited allergen binding to IgE antibody,
thereby inhibiting mast cell degranulation17. HBI (5) was composed of the NF hapten (Kd of
41 ± 4 μM for IgEDNP) conjugated to a nucleotide-binding site ligand, indole-3-butyric acid
(IBA; Kd of 4.5 ± 0.6 μM for IgE), with an ethylene glycol linker (Fig. 5a). This design
enabled simultaneous targeting of the antigen-binding site as well as of the adjacent
nucleotide-binding site located in the Fab of antibodies (Fig. 1d). Simultaneous bivalent
binding to both sites provided HBI with greater than 120-fold enhancement in avidity for
IgEDNP compared to monovalent NF17. In this study, we investigated the potential of HBI to
inhibit mast cell degranulation stimulated by HtTA [dansyl2NF2] by selectively and
exclusively inhibiting the weak-affinity epitope interactions, specifically the NF-IgEDNP
interactions. We predicted that HBI would partially inhibit the binding of HtTA
[dansyl2NF2] to mast cell-bound IgE by blocking the NF-IgEDNP interaction and that this
partial inhibition of allergen binding would effectively lower the valency of the allergen,
decreasing its potential to stimulate a response. To test our hypothesis, RBL cells were
primed with an equimolar solution of IgEDNP and IgEdansyl and then were exposed to HtTA
[dansyl2NF2] with increasing concentrations of the HBI (Fig. 5b). HBI inhibited the
degranulation response with a half-maximum effective concentration of 2 μM. The
individual components of HBI, ethylene glycol-conjugated NF as a monovalent inhibitor
(MI, 6; Fig. 5a) or IBA did not inhibit degranulation (Fig. 5c,d). These results demonstrated
that both moieties, IBA and NF, were required for the enhanced avidity of HBI for IgEDNP
that enabled the competitive inhibition of HtTA [dansyl2NF2] binding to IgEDNP. An
additional experiment was performed using the weak-affinity allergen HmTA [NF4] as the
inhibitor, and, as expected, HmTA [NF4] did not inhibit HtTA [dansyl2NF2] degranulation
as the tetravalent allergen design only allows monovalent binding to a single IgE and
therefore does not provide avidity enhancement for IgE (Supplementary Fig. 6). Next, to
demonstrate the specificity of the HBI for the NF-IgEDNP interaction, HmTA [dansyl4] was
used in place of HtTA [dansyl2NF2]. As NF does not bind IgEdansyl, HBI did not inhibit
HmTA [dansyl4]–induced degranulation (Fig. 5e). Combined, these studies demonstrated
that partial inhibition of HtTA [dansyl2NF2]–IgE binding by HBIs, which exclusively inhibit
only the weak affinity NF-IgEDNP interactions, was sufficient to prevent mast cell
degranulation.
HtTA induced degranulation in PCA mouse allergy model
The next step in validating the HtTA experimental system was to demonstrate the ability of
HtTA to induce an allergic response in vivo. We selected the passive cutaneous anaphylaxis
(PCA) mouse allergy model, a well-established model for studying anaphylaxis in vivo19,37.
The HtTA design requires the presence of two IgE antibodies each specific for a different
hapten to stimulate degranulation. Consequently, a mixture of 50 ng of IgEDNP and IgEdansyl
(right ear) or PBS (left ear) was injected intradermally into C57BL/6 mice. Twenty-four
hours later, 1.5 nmol of HtTA [dansyl2NF2] was injected intravenously, causing swelling in
the ear that received the IgE injection. Then, by comparing the tissue thickness of the ear
that received the IgE injection to the ear that received the PBS injection using both
micrometer measurements and histology, the severity of the allergic reaction was quantified.
The 1.5-nmol dose of HtTA [dansyl2NF2] corresponded to an initial blood concentration of
∼1,000 nM, slightly above the concentration that elicited the maximum degranulation
response in vitro (assuming mouse blood volume of 1.5 mL). HtTA [dansyl2NF2]
significantly increased tissue swelling 2 h after challenge when compared with the naive
group (P<0.05, Fig. 6). Mice treated with DNP-BSA were used as a control and showed a
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similar increase in ear thickness (Supplementary Fig. 7). These results validated the utility of
the HtTA design as an experimental model system that enables both in vitro and in vivo
evaluation of mast cell activation.
HBI inhibits degranulation in PCA mouse allergy model
To evaluate the therapeutic potential of HBI, we next evaluated its inhibitory potential in the
PCA mouse allergy model. C57BL/6 mice were injected intradermally with an equimolar
mixture of IgEdansyl and IgEDNP (right ear) and PBS (left ear). Twenty-four hours later, mice
were challenged intravenously with 1.5 nmol HtTA [dansyl2NF2] alone or in combination
with HBI as indicated in Figure 6. The amounts of HBI, 0.5 nmol, 5 nmol and 10 nmol per
mouse, were chosen on the basis of the in vitro inhibition data and correspond to initial
blood concentrations of ∼0.3–7 μM (1.5-ml blood volume), approximating the range where
inhibition was observed in vitro. HBI significantly inhibited ear swelling when compared to
nontreated mice in a dose-dependent manner, reaching near-complete inhibition at 10 nmol
(P<0.05, Fig. 6). This result indicated that HBI blocks the effects of HtTA [dansyl2NF2] on
tissue inflammation and edema induced by mast cell degranulation. Additionally, these
results provided further evidence that inhibition of all of the IgE epitopes on an allergen is
not required to effectively inhibit the degranulation response. In fact, inhibition of only a
few low-binding epitopes may be sufficient to prevent mast cell degranulation, thus
highlighting the therapeutic potential of the HBI design.
Discussion
Previous studies have addressed the role of high-affinity epitopes in mast cell degranulation
by using simplified allergen models; however, the importance of low-affinity epitopes have
not been sufficiently or properly evaluated. In this study, we established a well-defined
synthetic tetravalent allergen system that models the epitope heterogeneity and polyclonal
response of natural allergy systems through the multivalent presentation of high- and low-
affinity hapten molecules on the same scaffold. The bivalent presentation of each hapten on
the HtTA required the presence of two distinct IgE antibodies to elicit a mast cell
degranulation response. As such, the HtTA system better reflected the complexity of IgE-
epitope interactions observed in natural allergy systems and allowed for the elucidation of
the role weak-affinity epitopes have in mast cell degranulation. The tetravalency of the
synthetic allergens provided a realistic approximation of the number of immunodominant
epitopes present in several common allergens, and having precise control over the valency
and structure of the scaffold enabled us to study the effect of affinity on mast cell
degranulation without other confounding factors.
Using the HtTA allergen system, we demonstrated that low-affinity epitopes have an
important role in mast cell degranulation when presented in combination with high-affinity
epitopes on a multivalent allergen. The importance of low-affinity epitopes was
demonstrated with the synthetic allergen HtTA [dansyl2NF2], which was a potent stimulator
of mast cell degranulation, whereas a tetravalent version of NF, HmTA [NF4], and a bivalent
version of dansyl, HmBA [dansyl2], did not elicit a response. These results challenge the
previous theory that due to the extremely low IgE serum concentration, IgE must have a
moderate to high affinity for the specific allergen to stimulate mast cell degranulation38.
Combined, these experiments illustrate the importance of valency, affinity and cooperativity
in allergen-IgE binding interactions in mast cell degranulation, thus highlighting the
importance of weak-affinity epitopes in the induction of an allergic response.
To evaluate the therapeutic potential of selective inhibition of weak-affinity epitopes for the
inhibition of an allergic response, we used a molecular engineering approach to design the
HBI. The HBI was engineered to selectively inhibit only the weak-affinity hapten-IgE
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interactions by simultaneously targeting the antigen- and nucleotide-binding sites present on
the Fab arm of antibodies. The simultaneous bivalent binding provided the HBI with 120-
fold enhancement in affinity for IgEDNP compared to monovalent NF, making it a potent
inhibitor of mast cell degranulation. Markedly, HBI was a potent inhibitor of HtTA-induced
mast cell degranulation in both the in vitro RBL mast cell model and the in vivo PCA mouse
model of allergy. Using the HBI design in conjunction with the HtTA allergy model, we
demonstrated that inhibition of every epitope-IgE interaction on an allergen was not required
for complete inhibition of mast cell degranulation. Rather, partial inhibition of allergen
binding to the mast cell–bound IgEs to reduce the allergen valency was sufficient to inhibit
the overall mast cell degranulation response. Combined, the results presented here
demonstrate the utility of the conserved nucleotide-binding site for the inhibition of allergic
reactions and established the HBI design as an effective inhibitor of mast cell degranulation.
A major challenge in the current therapies used to treat allergic responses involves the
nonspecific suppression of the immune system that puts patients at risk for infections and
generates other side effects. Therefore more selective treatment options are needed. Given
that most allergens have one to five immunodominant epitopes and that selective inhibition
of only a few epitopes are sufficient to inhibit mast cell degranulation, short peptide
sequences that mimic an IgE epitope can be used in the HBI design as potential therapeutics
for the selective inhibition of food allergies, environmental allergies and asthmas.
Online Methods
Synthesis of the tetravalent and bivalent synthetic allergens
The synthetic allergens were synthesized using Fmoc solid phase synthesis as previously
described33. Fmoc-protected residues were activated with HBTU or HATU in DMF with
DIEA for 3 min, and coupling was monitored with Kaiser tests. Fmoc protecting groups
were removed by three exposures to 20% piperidine in DMF for 3 min. The synthetic
allergens were synthesized using multiple lysine derivatives to achieve branching while N-
Fmoc-amido-dPEG8-acid was used to provide the EG8 linkers. The syntheses of the
synthetic allergens were identical except for the conjugation of the different haptens. The
synthetic strategy was as follows: Boc-Lys(Fmoc)-OH was conjugated to NovaPEG Rink
Amide resin. After removal of the Fmoc group, a second Boc-Lys(Fmoc)-OH group was
added to the molecule, and Fmoc was removed. Next, Fmoc-Lys(ivDde)-OH was
conjugated to the molecule. After removal of the Fmoc group, Fmoc-Lys(Fmoc)-OH was
conjugated to the ligand to facilitate branching. Both Fmoc groups were removed
simultaneously, providing two primary amines for the conjugation of the ethylene glycol
linkers. After removing the Fmoc groups on the ethylene glycol linkers, Boc-Lys(Fmoc)-OH
was conjugated to each chain followed by the removal of the Fmoc groups. This provided
two primary amines for the conjugation of the first set of haptens, NF, dansyl or acetyl. The
next step was the removal of the orthogonal protecting group, ivDde, from the previously
conjugated lysine residue using 2% hydrazine in DMF. The same branching process was
repeated by sequentially conjugating Fmoc-Lys(Fmoc)-OH, N-Fmoc-amindo-dPEG8-acid
and Boc-Lys(Fmoc)-OH to the molecule, thus providing two additional primary amines for
the conjugation of the second set of haptens, dansyl or NF. Conjugation of the haptens was
achieved using: dansyl chloride (5-(dimethylamino)naphthalene-1-sulfonyl chloride) for
dansyl, 5-nitro-2-furoic acid for NF and acetic anhydride to create the acetyl group.
Following synthesis, all of the molecules were cleaved from the resin by two exposures to
92:4:4 TFA/H2O/TIS for 30 min. The TFA solution was removed under vacuum, and the
molecule was purified using RP-HPLC with a semipreparative Zorbax C18 column (9.4 mm
× 250 mm) with a linear solvent gradient of 2.5% min–1 increments in acetonitrile at a 4.0
mL/min flow rate. The purified molecules were characterized with a Bruker micrOTOF II
mass spectrometer. Purity was determined with the described HPLC system using a Zorbax
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C18 analytical column (4.6 mm × 150 mm). The purity of all of the synthesized ligands was
estimated to be >97% (Supplementary Fig. 9). The calculated exact mass of HtTA
[dansyl2NF2] (C164H283N27O57S2) was 3,606.9518 Da; found 3,607.9477 Da. The
calculated exact mass of HmTA [dansyl4] (C178H303N27O53S4) was 3,795.0727 Da;
found 3,796.0856 Da. The calculated exact mass of HmTA [NF4] (C150H263N27O61) was
3,418.8308 Da; found 3,419.84091 Da. The calculated exact mass of HmBA [dansyl2]
(C158H285N25O51S2) was 3,412.9918 Da; found 3,414.0026 Da. Characterization matched
literature values29,33.
Synthesis of HBI
The HBI was synthesized using Fmoc solid phase synthesis as previously described in
detail17. The purity was estimated to be >97% (Supplementary Fig. 9) by an analytical
injection using the previously described HPLC system and was characterized with a Bruker
micrOTOF II mass spectrometer. The calculated exact mass of HBI (C38H56N6O13) was
804.3905 Da; found 805.3928 Da. Characterization matched literature values17.
Synthesis of BSA-conjugated allergens
NF was conjugated to BSA using N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC), and dansyl was conjugated to BSA using dansyl chloride as
previously described17. BSA conjugates were purified using 0.5 mL 10-kDa molecular
weight cut-off spin concentrators (Millipore), and purity was determined using RP-HPLC
and found to be >95% (Supplementary Fig. 8)
Fluorescence quenching assay for determination of IgE-hapten binding affinities
The monovalent binding constants of NF and dansyl for IgEDNP and IgEdansyl were
determined using the previously described fluorescence quenching assay17. Briefly, NF and
dansyl quench the fluorescence from the IgE tryptophan residues, occurring at 335 nm, only
when the two molecules are in proximity to each other (<10 nm). The monovalent haptens
were titrated into a 96-well plate containing a 200-μL solution of 10 nM IgE in PBS. All of
the experiments were repeated in at least triplicate.
IgE-HtTA complex formation
Dynamic light scattering experiments were performed with a Malvern Zetasizer Nano S.
Monomeric IgE was evaluated at a concentration of 0.8 μM (0.4 μM IgEDNP and 0.4 μM
IgEdansyl) in PBS. IgE complex formation was evaluated with an IgE concentration of 0.8
μM (0.4 μM IgEDNP and 0.4 μM IgEdansyl) with a stoichiometric amount of HtTA (0.4 μM)
in PBS with an estimated refractive index of 1.45.
RBL degranulation assay
RBL cells and IgEDNP were kindly provided by Dr. B Wilson (University of New Mexico),
and IgEdansyl (clone 27-74) was purchased from BD Biosciences. RBL cells were
maintained as described previously16. For the degranulation assays, 100 μL of cells were
plated at 0.5 × 106 cells/mL in a 96-well plate and were incubated for 24 h followed by a 2-h
incubation with the IgE antibodies as indicated in Figures 4 and 5 at a total IgE
concentration of 1 μg/mL. Cells were washed immediately before experiments and were
stimulated with the concentration of allergen as indicated in Figures 4 and 5 for 60 min
unless otherwise stated. When testing the allergy inhibitors, the inhibitor was added to cells
30 min before the allergen. Degranulation was detected spectroscopically by measuring the
activity of the granule-stored enzyme β-hexosaminidase secreted into the supernatant on the
substrate p-nitrophenyl-N-actyl-β-O-glucosamine. All of the degranulation assays were
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repeated in at least triplicate. In all of the experiments, the total IgE concentration was kept
constant at 1 μg/mL.
Animals
C57BL/6 female mice (7–8 weeks) were obtained from Harlan Biosciences (Indianapolis,
IN). Mice were maintained in pathogen-free conditions, and studies were approved by the
Indiana University Institutional Animal Care and Use Committee.
PCA
PCA was performed as previously described19. Briefly, mice were injected intradermally
with PBS (left ear) and an equimolar solution of IgEDNP and IgEdansyl (100 ng total IgE)
(right ear). After 24 h, mice were injected intravenously with HtTA [dansyl2NF2] (1.5 nmol)
and treated with the amount of HBI indicated in Figure 6. The thickness of ears was
measured before HtTA [dansyl2NF2] and at 1 h and 2 h after challenge. The data were
expressed as change in thickness compared with values before HtTA [dansyl2NF2]
inoculation.
Statistical analysis
A one-way analysis of variance (ANOVA) for multiple comparisons was performed, and P
< 0.05 was considered statistically significant as indicated in Figure 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Design of the HtTA and the HBI for the selective inhibition of mast cell degranulation
(a) Structure of the melon allergen Cuc m 2 with the four identified epitopes displaying both
high and low affinity for IgE antibodies. A HtTA consisting of two distinct haptens each
with a valency of 2 was synthesized to model the multiple different epitopes present on a
natural allergen such as Cuc m 2. To mimic the high- and low-binding IgE epitopes, the first
hapten was chosen to have a high affinity and the second hapten was chosen to have a low
affinity for their respective IgEs. (b) In an allergic reaction, the allergen binds the polyclonal
IgE antibodies present on the surface of mast cells. Multivalent allergen binding to surface-
bound IgE antibodies cause aggregation of the IgE receptor, FcsRI, initiating a signaling
cascade that results in mast cell degranulation. (c) The HtTA design mimics multiple distinct
epitopes as well as the polyclonal IgE response present in natural allergic responses by using
two IgE antibodies, IgE-1 and IgE-2, each with different hapten specifcity. (d) Crystal
structure of an IgG antibody with enlarged Fab region to demonstrate the location of the
nucleotide- and antigen-binding sites. The HBI was designed to simultaneously bind both
the antigen- and the nucleotide–binding sites on an IgE. (e) HBI selectively inhibits the low-
affinity hapten/IgE interactions, effectively lowering the valency of the allergen rendering it
incapable of causing sufficient IgE cross-linking to stimulate a degranulation response.
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Figure 2. Chemical structures of the haptens and tetravalent synthetic allergens
(a) Structures of the haptens NF and dansyl used to synthesize the allergens. (b) The
structure of the tetravalent scaffold and the compositions of the HtTA, HmTAs and HmBA
are shown.
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Figure 3. Characterization of hapten/IgE binding interactions
(a) Binding curves for monovalent dansyl (●) binding to IgEdansyl and monovalent NF (□)
binding to IgEDNP. Binding was observed by monitoring the fluorescence quenching of the
tryptophan residues in the IgE antibodies. Values for the binding constants are Kd,dansyl = 54
± 4 nM and Kd,NF = 41 ± 4 μM. Control experiments with NF-IgEdansyl and dansyl-IgEDNP
did not show any cross-reactivity in the hapten IgE pairs (Supplementary Fig. 1). Data
represent the mean ± s.d. of triplicate experiments. (b) Dynamic light scattering data
demonstrate the aggregation of IgEDNP (left) and IgEdansyl (right) in response to the addition
of a stoichiometric concentration of HtTA. The size of the equimolar solution of IgEDNP
and IgEdansyl was 10 nm and was increased to 20 nm upon the addition of HtTA
[dansyl2NF2].
Handlogten et al. Page 15
Nat Chem Biol. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Mast cell degranulation in response to tetravalent synthetic allergens
(a) RBL cells were primed with IgEDNP, IgEdansyl or an equimolar solution of both
antibodies. Dansyl14-BSA and NF17-BSA both stimulated a response when the hapten-
specific IgE was present on the surface of the mast cells, but did not stimulate a response if
it was absent. (b) RBL cells were primed with an equimolar solution of IgEDNP and
IgEdansyl and then exposed to increasing concentrations of the indicated synthetic allergen.
(c) RBL cells were primed with an equimolar solution of IgEDNP and IgEdansyl followed
by exposure to a constant allergen concentration for the indicated period of time. HtTA
[dansyl2NF2] and HmTA [dansyl4] were used at 500 nM, whereas HmTA [NF4] and HmBA
[dansyl2] were used at 10 μM. Triton X (1%) was used to determine the percent
degranulation. Data represent the mean ± s.d. of triplicate experiments.
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Figure 5. Inhibition of mast cell degranulation via the HBI design
(a) Structures of the HBI and the control molecule MI are shown. HBI is composed of the
NF hapten molecule conjugated to IBA with an ethylene glycol linker, whereas MI is
composed of the ethylene glycol– conjugated NF hapten only. (b) The inhibitory potential of
HBI was evaluated using mast cells primed with an equimolar solution of IgEDNP and
IgEdansyl and stimulated with 500 nM of HtTA [dansyl2NF2]. HBI effectively inhibited mast
cell degranulation with a half-maximum inhibitory concentration of 2 μM. (c,d) In control
experiments performed with MI (c) or IBA (d), no inhibition of mast cell degranulation was
observed. (e) In another control experiment, HmTA [dansyl4], was used in place of HtTA
[dansyl2NF2] to stimulate degranulation, and HBI was unable to inhibit the response. Triton
X (1%) was used to determine the percent degranulation. Data represent the mean ± s.d. of
triplicate experiments.
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Figure 6. Inhibition of PCA via the HBI in an in vivo mouse allergy model
(a) Ear swelling during PCA was determined 1 h and 2 h after systemic HtTA [dansyl2NF2]
challenge in mice receiving no HBI treatment or 0.5 nmol, 5 nmol or 10 nmol of HBI. The
data was expressed as change in thickness compared with values before HtTA [dansyl2NF2]
inoculation, measured with a micrometer caliper. Naive mice did not receive injection of
IgE, HtTA [dansyl2NF2] or HBI. (b) Ear tissue was stained with hematoxylin and eosin stain
at 2 h after systemic challenge. Representation of dermal thickness in naive (left), HtTA
[dansyl2NF2]–challenged (middle) and HtTA [dansyl2NF2]–challenged (plus 10 nmol HBI)
(right) mice with HBI are shown. Scale bar, 200 μm. Data represent the mean ± s.e.m. of
five mice from two independent experiments. *P < 0.05.
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